RxDoctor Payments Data

Gregory Kosters, DO

Family Medicine · Sibley, IANPI 1821076886

Payments from drug & device makers

$2,452in general payments, 2019–2025

Across 144 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$433
  • Astellas Pharma US Inc$377
  • AstraZeneca$223
  • Novartis$207
  • Novo Nordisk$200
  • Pfizer$185
  • plus $828 from 16 others

What the payments were for

  • Food & beverage$2,25292%
  • Education$2008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,452 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$149,457
Medicare patients
390
Services billed
6,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$84,791
XareltoRivaroxaban56$37,893
JardianceEmpagliflozin58$35,726
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$25,057
MyrbetriqMirabegron60$20,447
OzempicSemaglutide18$16,579
Synjardy XrEmpagliflozin/Metformin Hcl24$13,763
ArexvyRsvpref3 Antigen/As01e/Pf37$11,457
Breo ElliptaFluticasone/Vilanterol27$10,704
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$8,551
FarxigaDapagliflozin Propanediol11$7,341
Repatha PushtronexEvolocumab12$6,865
Spiriva RespimatTiotropium Bromide12$6,573
Levothyroxine Sodium633$5,717
Spiriva HandihalerTiotropium Bromide11$5,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$185$84,791106 claims
Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat$102$56,06294 claims
Johnson & JohnsonXarelto$176$37,89356 claims
Astellas Pharma US IncMyrbetriq$377$20,44760 claims
Novo NordiskOzempic$200$16,57918 claims
AstraZenecaFarxiga$223$7,34111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Sibley

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →